---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Economic burden and healthcare resource utilization. Topics: National health care expenditures and events associated with hypertension: MEPS 2019; Annual costs of high blood pressure: CDC; Incremental expenditure for adults with hypertension: MEPS 2003 to 2014; Direct and indirect cost and hospital, office, and emergency department use: AHA statistics; 8 further topics. 12 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### National health care expenditures and events associated with hypertension: MEPS 2019

> “Hypertension was associated with $2,759 (95% confidence interval [CI]: $2,039, $3,479) in health care expenditures and 10.3 (95% CI: 9.3, 11.3) health care events, including prescriptions filled, in 2019 per person.”
> “Estimated annual national health care expenditures associated with hypertension were about $219.2 billion in the United States in 2019. This includes $32.5 billion in prescribed medication purchases, $70.2 billion in outpatient services, and $79.4 billion in inpatient services. The number of health care events associated with hypertension was about 817.4 million, including 538.2 million prescribed medication purchases, 168.1 million outpatient visits, 3.5 million inpatient visits, and 6.0 million ED visits”
> “Results from this study indicated that hypertension was associated with more than 10% of the total health care expenditures and events at national level”

Source: [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11585433/)

<a id="topic-2.2.1.8.2-2"></a>

### Annual costs of high blood pressure: CDC

> “Annual costs associated with high blood pressure were an estimated $219 billion in the United States in”

Source: [CDC High Blood Pressure Facts (2026)](https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html)

<a id="topic-2.2.1.8.2-3"></a>

### Incremental expenditure for adults with hypertension: MEPS 2003 to 2014

> “Relative to individuals without hypertension, individuals with hypertension had $1920 higher annual adjusted incremental expenditure, 2.5 times the inpatient cost, almost double the outpatient cost, and nearly triple the prescription medication expenditure. Based on the prevalence of hypertension in the United States, the estimated adjusted annual incremental cost is $131 billion per year higher for the hypertensive adult population compared with the nonhypertensive population.”

Source: [Kirkland et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6015342/)

<a id="topic-2.2.1.8.2-4"></a>

### Direct and indirect cost and hospital, office, and emergency department use: AHA statistics

> “The estimated direct and indirect cost of HBP for 2020 to 2021 (annual average) was $49.0 billion”
> “Estimated US health care expenditures for hypertension in 2016 were $79 (95% CI, $72.6–$86.8) billion. Of 154 health conditions, hypertension ranked 10th in health care expenditures.”
> “From 2011 to 2021, the number of inpatient discharges from short-stay hospitals with HBP as the principal diagnosis increased from 296 253 to 1 311 528. The number of discharges with any listing of HBP increased from 16 112 764 to 17 160 070 in that same time period.”
> “In 2019, 56 795 000 of 1 036 484 000 physician office visits had a primary diagnosis of essential hypertension”
> “There were 779 438 ED discharges with a principal diagnosis of essential hypertension in 2021”

Source: [Martin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12256702/)

<a id="topic-2.2.1.8.2-5"></a>

### US spending on treatment of hypertension by type of care and payer, 2019

| Measure | Treatment of hypertension |
| --- | --- |
| Total 2019 spending, US$ billions (95% CI) | “35.57 (34.9-36.2)” |
| Share of spending in adults older than 65 years, % | “56.7” |
| Inpatient care, % | “0.3” |
| Emergency department, % | “4.5” |
| Ambulatory care, % | “41.8” |
| Prescribed retail pharmaceuticals, % | “39.5” |
| Nursing facility, % | “4.0” |
| Medicare, % | “39.9” |
| Medicaid, % | “14.3” |
| Private insurance, % | “29.3” |
| Out of pocket, % | “16.6” |

Source: [Dieleman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11829247/)

<a id="topic-2.2.1.8.2-6"></a>

### Resource use and costs with uncontrolled compared with controlled blood pressure in apparent treatment-resistant hypertension and stage 3 or 4 CKD: US claims, 3966 patients

> “This retrospective cohort study used linked IQVIA Ambulatory EMR–US and IQVIA PharMetrics Plus claims databases.”
> “Of 3,966 patients with stage 3–4 CKD using ≥3 antihypertensive medications, 2,479 had uncontrolled BP and 1,487 had controlled BP. After adjusting for baseline differences, patients with uncontrolled vs. controlled BP had a higher risk of MACE+ (HR [95% CI]: 1.18 [1.03–1.36]), ESRD (1.85 [1.44–2.39]), inpatient hospitalization (rate ratio [95% CI]: 1.35 [1.28–1.43]), and outpatient visits (1.12 [1.11–1.12]) and incurred higher total medical and pharmacy costs (mean difference [95% CI]: $10,055 [$6,741–$13,646] per patient per year).”
> “Total medical costs were driven primarily by outpatient visits (+$6,514) and inpatient hospital admissions (+$3,202).”
> “Similarly, in our sensitivity analysis using a BP threshold of ≥140/90 mm Hg, there were increases in inpatient hospitalizations (HR, 1.26) and outpatient visits (HR, 1.18), and total costs increased by approximately $9,000.”

Source: [Bakris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11094384/)

<a id="topic-2.2.1.8.2-7"></a>

### Outpatient visit frequency in apparent treatment-resistant hypertension: REGARDS linked with Medicare claims

> “We studied the frequency and intensity of care for aTRH among participants aged 65 years and older in the US-based REGARDS study linked with Medicare claims.”
> “Among 4650 participants with hypertension, 468 (10.1%) had UaTRH, 247 (5.3%) had CaTRH, and 3935 (84.6%) had hypertension but did not have aTRH. For hypertension-related visits, those with UaTRH saw primary care physicians and cardiologists more frequently than those without aTRH (mean primary care visits per year: 2.77 vs 2.27, P < .001; cardiologists: 0.50 vs 0.35, P = .014).”
> “Many people with UaTRH are not seen more than once per year for hypertension and may benefit from increased care.”

Source: [Vemulapalli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8218938/)

<a id="topic-2.2.1.8.2-8"></a>

### Added expenditure attributed to apparent resistant hypertension: review

> “Compared with nonresistant hypertension, RHT is associated with an added economic burden on both the US health care system and individual patients.”
> “Apparent RHT is estimated to increase US health care expenditures by $11 billion to $18 billion per year over those associated with non-resistant hypertension”
> “Suboptimal adherence to prescribed medications also increases total health care costs”

Source: [Flack et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11533979/)

<a id="topic-2.2.1.8.2-9"></a>

### Annual costs of cardiovascular health states used in the ICER model, 2025 US dollars

> “For acute cardiovascular events, a first-cycle cost reflecting acute hospitalization and care was applied in the cycle of the event, followed by ongoing annual costs for the post-event state in subsequent cycles.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Health state | Direct medical cost | Productivity cost (modified societal perspective) |
| --- | --- | --- |
| Hypertension (annual) | “$3,211” | Not reported |
| Stroke (acute and annual; annual for productivity) | “$20,442 / $20,697” | “$16,781” |
| Myocardial infarction (acute and annual; annual for productivity) | “$25,832 / $17,106” | “$19,028” |
| Coronary heart disease (annual) | “$13,798” | “$7,092” |
| Heart failure (index hospitalization and annual; annual for productivity) | “$16,671 / $33,890” | “$16,004” |
| End-stage kidney disease (annual) | “$108,953” | “$17,650” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.8.2-10"></a>

### Productivity loss associated with hypertension in the United States: review of 27 studies

> “Twenty-seven articles met the inclusion criteria.”
> “Annual absenteeism was estimated to cost more than $11 billion, nationally controlling for sociodemographic characteristics. The annual additional costs per person were estimated at $63 for short-term disability, $72–$330 for absenteeism, and $53–$156 for presenteeism, controlling for participant characteristics; and may be as high as $2362 for absenteeism and presenteeism when considered in combination.”
> “The annual additional time loss per person was estimated as 1.3 days for absenteeism, controlling for common hypertension comorbidities, including stroke and diabetes; and 15.6 days for work and home productivity loss combined, controlling for sociodemographic characteristics.”
> “The loss from absenteeism alone might be more than 20% of the total medical expenditure of hypertension.”

Source: [MacLeod et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9536345/)

<a id="topic-2.2.1.8.2-11"></a>

### Antihypertensive adherence, medical costs, and disability costs in commercially insured adults: MarketScan 2019

> “We conducted cross‐sectional analyses using MarketScan databases, which included individuals aged 18 to 64 years with noncapitated health insurance plans in 2019.”
> “54.4% adhered to antihypertensives.”
> “Per person, antihypertensive medication adherence was associated with $1441 lower total medical costs, $11 lower sick absence costs, $291 lower short‐term disability costs, and $69 lower long‐term disability costs. Per 1000 individuals, medication adherence was associated with lower health care use, including 200 fewer emergency department visits and 90 fewer inpatient admissions, and productivity‐related outcomes, including 20 fewer sick absence days and 442 fewer short‐term disability days.”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11935718/)

<a id="topic-2.2.1.8.2-12"></a>

### Projected health care costs of cardiovascular risk factors including hypertension through 2050

> “We used nationally representative health, economic, and demographic data to project health care costs attributable to key cardiovascular risk factors (hypertension, diabetes, hypercholesterolemia) and conditions (coronary heart disease, stroke, heart failure, atrial fibrillation) through 2050.”
> “Annual inflation-adjusted (2022 US dollars) health care costs of cardiovascular risk factors are projected to triple between 2020 and 2050, from $400 billion to $1344 billion.”

Source: [Kazi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38832515/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
